The short version: I'm giving Protopep 5 out of 10, the highest of the other SA shops I've graded so far. It earns it: 14 of its 37 posts list real sources, and a couple are refreshingly straight about how thin the human evidence is. But its citations page mostly links to the wrong papers, several posts are written as personal dose guides, and the lab reports it promises aren't anywhere on the site.
What I looked at: protopep.co.za, all 37 blog posts (12 read in full), the Research Citations page with every PubMed and DOI link checked, 41 product descriptions and 10 live product pages, the dose calculator, Peptide Finder, pen tutorial, FAQ and policies. Research on 14 October, screenshots on 15 October 2026.
The score, broken down
| What I marked | Score | Why |
|---|---|---|
| Is it clear? | 1 / 2 | The 2026 posts are well laid out. Across the site, the lab-report promise comes in five versions and the returns rule in three, and two posts show raw code to readers. |
| Is it useful? | 1 / 2 | The mixing, storage and purity guides and the calculator are genuinely useful. Too many posts are personal dose guides with a lab-coat label. |
| Are the facts right? | 1 / 2 | Some big claims hold, like an FDA approval and an approved dose. Others don't: a tirzepatide start dose, a trial's population, a trial phase that doesn't exist. |
| Does it show the evidence? | 1 / 2 | More real references than any SA shop I've graded. Undercut by a citations page whose links mostly open unrelated papers, and some “sources” that are other peptide sellers. |
| Is it honest about downsides? | 1 / 2 | Two posts are candid about weak evidence. None of the 5 weight-loss drug posts mentions the official thyroid warning, and only 1 of 37 posts mentions doping rules. |
| Total | 5 / 10 | Trying to show its working, and getting the working wrong. |
The supplier checks
| Check | Result | Why |
|---|---|---|
| Lab reports | Red | The home page says every batch comes with a lab report. The contact page says samples are “available upon request”. None is published: no lab named, no batch, no date. |
| Claims & dosing | Red | A “Patient Profile” case study with personal doses, injection instructions, a bedtime dose “for treatment-resistant insomnia”, and a tool that picks products by “health goal or condition”, while the terms say products are “solely for in vitro research”. |
| Basics | Amber | Email, phone, hours, the paying company's name, clear shipping costs and an 18+ rule. But the terms still say “[Your Business Address]”, the policy emails use a different domain, and the returns rules contradict each other. |
What they got right
Honest about thin evidence, in places. Their BPC-157 overview has a section called “The Human Evidence Gap” that says plainly most research is in rodents, mostly from one lab group. Their tesamorelin post ranks the drug's evidence above a stack they also sell, and says that stack lacks large human trials. That's rare.
They cite things. 14 of 37 posts carry reference lists, mostly to PubMed and journal sites. Their SS-31 post correctly reports the drug's 2025 FDA approval for Barth syndrome, and their PT-141 post states the approved dose correctly.
Sensible basics. The mixing, storage and purity guides are sound, the purity guide even teaches readers what a missing lab chart means, and the calculator explains its units properly. Product pages have no dose tables, and the shop lists shipping costs openly.
What dragged it down
A citations page that points at the wrong papers. The Research Citations page calls itself “Peer-reviewed studies supporting our dosing protocols” and says every citation links to PubMed. I checked all 21 PubMed links. Only 3 open the paper that's cited. The BPC-157 healing study links to a paper about low-calorie diets. The TB-500 heart study opens a paper on an ion channel's structure. The tesamorelin trial opens a paper on liver shunts in cirrhosis. Most of the real studies do exist, just under different numbers. No post links to this page either.
“Peer-reviewed studies supporting our dosing protocols.”
A “case study” that reads like a prescription. A post about one woman's 42 kg weight loss uses medical headings like “Patient Profile” and “Peptide Therapy”, gives her weekly tirzepatide and retatrutide doses, and calls itself a template for others. It says tirzepatide usually starts at “2.5 mg every two weeks”. The official labels say 2.5 mg once a week is the starting dose. The post has no research-use line, never mentions the labels' boxed warning about thyroid tumours, and its own figures don't add up: its body-scan table shows lean mass falling while the headline says all the weight lost was fat. I'm not repeating any doses here.
Research use only, in the small print. The terms say buyers will use products “solely for in vitro research purposes”. Meanwhile a hair-loss post says to “Inject subcutaneously in the abdomen or thigh, preferably in the evening”, a sleep post offers a bedtime dose “For individuals with treatment-resistant insomnia”, a rheumatoid arthritis post ranks eight of their products, the Peptide Finder sorts products by “health goal or condition”, product pages say how many days a vial lasts “at standard research doses”, and there's a pen-injection tutorial.
Facts that don't hold up.
| What they say | What I found |
|---|---|
| Tirzepatide typically starts at “2.5 mg every two weeks” (P03) | Both official tirzepatide labels start at 2.5 mg once a week. |
| A trial showed tesamorelin cut liver fat “in non-HIV adults with NAFLD” (P21) | The trial they cite was in people with HIV, published in 2019. Their reference list even changes the paper's title. |
| NA-931: “Phase 3 trials now underway” (P20) | The trial registry lists only Phase 1 and Phase 2 studies, and no results have been posted or published. |
| “All citations link to PubMed or original journal sources” (P09) | 18 of the 21 PubMed links open unrelated papers, and 14 of the 20 DOI links don't reach the cited paper. |
Lab reports promised, not shown. The home page says “Every batch comes with a certificate of analysis”, and the terms and returns page say the same. The contact page says “Sample Certificates of Analysis are available upon request”, and their own purity guide says third-party testing is for “select batches”. I found no report on any product page, and no lab named anywhere.
Missing warnings. None of their five weight-loss drug posts mentions the thyroid tumour warning on the official labels, or pancreatitis. Only one of 37 posts mentions that some of these peptides are banned in sport.
The basics. There's an email, a phone number, opening hours and a named paying company (in the FAQ). But the terms and privacy pages end with “Address: [Your Business Address]” and a phone number of “XXX-XXXX”, an unfinished template (P15). The policies give email addresses on protopep.com, a different domain from the shop. One page says returns within 14 days are fine (P17); the contact page says “we cannot accept returns once shipped” (P18). There's no street address, company registration or VAT number.
What would get them a better grade
- Fix the citations page so every link opens the paper it names, and link to it from the posts.
- Take down the patient-style case study and personal dose guides, or stop calling the products research use only.
- Correct the tirzepatide start dose, the tesamorelin trial population and the NA-931 trial phase.
- Publish the lab reports the home page promises: per batch, lab named, checkable.
- Add the official warnings (thyroid, pancreatitis) to the weight-loss posts, and a doping note where it applies.
- Finish the policy pages: a real address, one email domain, one returns rule.
Do that and I'll grade it again, here, in public. They're closer to a good grade than most.
Their side
Protopep can reply any time through this form. If they do, I'll add it here word for word.
Spotted something I got wrong? Tell me. I fix facts fast and say what changed. I don't change a grade because someone complains, only when I've got a fact wrong or the supplier changes what they publish.
Evidence log
| Ref | What they said | Where | Seen |
|---|---|---|---|
| P01 | “Patient Profile and Baseline Measurements” | /blog/sarah-m-weight-loss-case-study-tirzepatide-retatrutide · saved | 15 Oct 2026 |
| P02 | Personal dose stated (not repeated here) | /blog/sarah-m-weight-loss-case-study-tirzepatide-retatrutide · saved | 15 Oct 2026 |
| P03 | “typically starting at 2.5 mg every two weeks” | /blog/sarah-m-weight-loss-case-study-tirzepatide-retatrutide · saved | 15 Oct 2026 |
| P04 | Personal dose stated (not repeated here) | /blog/sarah-m-weight-loss-case-study-tirzepatide-retatrutide · saved | 15 Oct 2026 |
| P05 | “Inject subcutaneously in the abdomen or thigh, preferably in the evening” | /blog/hair-loss-retatrutide-glp1-protocol · saved | 15 Oct 2026 |
| P06 | “For individuals with treatment-resistant insomnia” | /blog/peptides-for-sleep-and-recovery · saved | 15 Oct 2026 |
| P07 | “Ranked by Evidence Strength” | /blog/peptides-for-rheumatoid-arthritis · saved | 15 Oct 2026 |
| P08 | “dosage protocols, and scientific insights into peptide therapy” | /blog · saved | 15 Oct 2026 |
| P09 | “Peer-reviewed studies supporting our dosing protocols” | /research-citations · saved | 15 Oct 2026 |
| P10 | “PMID: 30683819” | /research-citations · saved | 15 Oct 2026 |
| P11 | “Every batch comes with a certificate of analysis” | / · saved | 15 Oct 2026 |
| P12 | “Sample Certificates of Analysis are available upon request” | /contact · saved | 15 Oct 2026 |
| P13 | “Third-party verification for select batches” | /blog/understanding-peptide-purity-hplc-mass-spectrometry · saved | 15 Oct 2026 |
| P14 | “5mg vial lasts ≈ 50 days supply at standard research doses.” | /product/bpc-157 · saved | 15 Oct 2026 |
| P15 | “Address: [Your Business Address]” | /terms-conditions · saved | 15 Oct 2026 |
| P16 | “Products will be used solely for in vitro research purposes” | /terms-conditions · saved | 15 Oct 2026 |
| P17 | “info@protopep.com within 14 days” | /return-policy · saved | 15 Oct 2026 |
| P18 | “we cannot accept returns once shipped” | /contact · saved | 15 Oct 2026 |
| P19 | “Select a health goal or condition” | /peptide-finder · saved | 15 Oct 2026 |
| P20 | “Phase 3 trials now underway” | /blog/na-931-oral-quadruple-agonist-weight-loss-muscle-preservation · saved | 15 Oct 2026 |
| P21 | “in non-HIV adults with NAFLD” | /blog/tesamorelin-vs-cjc-1295-ipamorelin-science-comparison · saved | 15 Oct 2026 |
| P22 | “The Human Evidence Gap” | /blog/bpc-157-body-protection-compound-research-overview · saved | 15 Oct 2026 |
Update log
- 15 Oct 2026: First published.
Sources
- Mounjaro (tirzepatide) US prescribing information: 2.5 mg once weekly start, boxed thyroid warning.
- Zepbound (tirzepatide) US prescribing information.
- Stanley et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV, 2019.
- ClinicalTrials.gov: NA-931 studies (Phase 1 and Phase 2 only).
- PubMed 30683819, the paper Protopep's BPC-157 citation actually links to.
